An Update on Advanced Therapies for Parkinson's Disease: From Gene Therapy to Neuromodulation

Overview

Journal Front Surg

Specialty General Surgery

Date 2022 Oct 10

PMID 36211256

Authors

Stephanie N Serva

Jacob Bernstein

John A Thompson

Drew S Kern

Steven G Ojemann

Affiliations

Soon will be listed here.

Abstract

Advanced Parkinson's disease (PD) is characterized by increasingly debilitating impaired movements that include motor fluctuations and dyskinesias. At this stage of the disease, pharmacological management can result in unsatisfactory clinical benefits and increase the occurrence of adverse effects, leading to the consideration of advanced therapies. The scope of this review is to provide an overview of currently available therapies for advanced PD, specifically levodopa-carbidopa intestinal gel, continuous subcutaneous apomorphine infusion, radiofrequency ablation, stereotactic radiosurgery, MRI-guided focused ultrasound, and deep brain stimulation. Therapies in clinical trials are also discussed, including novel formulations of subcutaneous carbidopa/levodopa, gene-implantation therapies, and cell-based therapies. This review focuses on the clinical outcomes and adverse effects of the various therapies and also considers patient-specific characteristics that may influence treatment choice. This review can equip providers with updated information on advanced therapies in PD to better counsel patients on the available options.

Citing Articles

Customizing Parkinson's care: sustaining continuous levodopa therapy post-gastrectomy.

Buonocore J, Ammendola M, Romano R, Morelli M, Gambardella A Neurol Sci. 2025; .

PMID: 39939502 DOI: 10.1007/s10072-025-08042-9.

Oligodendrocytes, the Forgotten Target of Gene Therapy.

Ozgur-Gunes Y, Le Stunff C, Bougneres P Cells. 2024; 13(23).

PMID: 39682723 PMC: 11640421. DOI: 10.3390/cells13231973.

Role of Neurosurgical Interventions in the Treatment of Movement Disorders Like Parkinson's Disease, Dystonia, and Tourette Syndrome.

Ranjan R, Chourey A, Kabir Y, Garcia Mata H, Tiepolo E, Fiallos Vinueza I Cureus. 2024; 16(10):e72613.

PMID: 39610627 PMC: 11603398. DOI: 10.7759/cureus.72613.

Gene Therapy for Parkinson's Disease Using Midbrain Developmental Genes to Regulate Dopaminergic Neuronal Maintenance.

Kim J, Chang M Int J Mol Sci. 2024; 25(22).

PMID: 39596436 PMC: 11594980. DOI: 10.3390/ijms252212369.

Transcranial direct current stimulation for Parkinson's disease: systematic review and meta-analysis of motor and cognitive effects.

Duan Z, Zhang C NPJ Parkinsons Dis. 2024; 10(1):214.

PMID: 39505889 PMC: 11542032. DOI: 10.1038/s41531-024-00821-z.

References

Martinez-Fernandez R, Rodriguez-Rojas R, Del Alamo M, Hernandez-Fernandez F, Pineda-Pardo J, Dileone M . Focused ultrasound subthalamotomy in patients with asymmetric Parkinson's disease: a pilot study. Lancet Neurol. 2017; 17(1):54-63. DOI: 10.1016/S1474-4422(17)30403-9. View

Skorvanek M, Bhatia K . The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues. Mov Disord Clin Pract. 2018; 4(1):21-31. PMC: 6174479. DOI: 10.1002/mdc3.12425. View

Lang A, Rodriguez R, Boyd J, Chouinard S, Zadikoff C, Espay A . Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2015; 31(4):538-46. PMC: 5064722. DOI: 10.1002/mds.26485. View

Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Antonini A . Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efﬁcacy, safety and patient selection. Funct Neurol. 2013; 27(3):147-54. PMC: 3812765. View

Kenney C, Simpson R, Hunter C, Ondo W, Almaguer M, Davidson A . Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007; 106(4):621-5. DOI: 10.3171/jns.2007.106.4.621. View

Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S . Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain. 2019; 142(3):512-525. PMC: 6391602. DOI: 10.1093/brain/awz023. View

Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K . A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther. 2010; 18(9):1731-5. PMC: 2956925. DOI: 10.1038/mt.2010.135. View

Prakash N, Simuni T . Infusion Therapies for Parkinson's Disease. Curr Neurol Neurosci Rep. 2020; 20(9):44. DOI: 10.1007/s11910-020-01062-2. View

Merello M, PIKIELNY R, Cammarota A, Leiguarda R . Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Clin Neuropharmacol. 1997; 20(2):165-7. DOI: 10.1097/00002826-199704000-00008. View

10.

Fan Y, Winanto , Ng S . Replacing what's lost: a new era of stem cell therapy for Parkinson's disease. Transl Neurodegener. 2020; 9:2. PMC: 6945567. DOI: 10.1186/s40035-019-0180-x. View

11.

Eisenberg H, Krishna V, Elias W, Cosgrove G, Gandhi D, Aldrich C . MR-guided focused ultrasound pallidotomy for Parkinson's disease: safety and feasibility. J Neurosurg. 2021; 135(3):792-798. DOI: 10.3171/2020.6.JNS192773. View

12.

Bernstein J, Kashyap S, Ray K, Ananda A . Infections in Deep Brain Stimulator Surgery. Cureus. 2019; 11(8):e5440. PMC: 6797017. DOI: 10.7759/cureus.5440. View

13.

Higuchi Y, Iacono R . Surgical complications in patients with Parkinson's disease after posteroventral pallidotomy. Neurosurgery. 2003; 52(3):558-71; discussion 568-71. DOI: 10.1227/01.neu.0000047817.60776.5c. View

14.

Ho A, Ali R, Connolly I, Henderson J, Dhall R, Stein S . Awake versus asleep deep brain stimulation for Parkinson's disease: a critical comparison and meta-analysis. J Neurol Neurosurg Psychiatry. 2017; 89(7):687-691. DOI: 10.1136/jnnp-2016-314500. View

15.

Young R, Vermulen S, Posewitz A . Gamma knife radiosurgery for the treatment of trigeminal neuralgia. Stereotact Funct Neurosurg. 1998; 70 Suppl 1:192-9. DOI: 10.1159/000056422. View

16.

Richardson R, Kells A, Rosenbluth K, Salegio E, Fiandaca M, Larson P . Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther. 2011; 19(6):1048-57. PMC: 3129792. DOI: 10.1038/mt.2011.11. View

17.

Kempster P, Frankel J, STERN G, Lees A . Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990; 53(11):1004-7. PMC: 488286. DOI: 10.1136/jnnp.53.11.1004. View

18.

Odekerken V, Boel J, Schmand B, de Haan R, Figee M, van den Munckhof P . GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up. Neurology. 2016; 86(8):755-61. DOI: 10.1212/WNL.0000000000002401. View

19.

Higuchi Y, Matsuda S, Serizawa T . Gamma knife radiosurgery in movement disorders: Indications and limitations. Mov Disord. 2016; 32(1):28-35. DOI: 10.1002/mds.26625. View

20.

Othman A, Rosebraugh M, Chatamra K, Locke C, Dutta S . Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa. J Parkinsons Dis. 2017; 7(2):275-278. PMC: 5438475. DOI: 10.3233/JPD-161042. View